BMS Looks to Galvanise Opdivo’s Prospects with Halozyme’s Technology
By Jasmine Kalsi & Heather Cartwright
Pharma Deals Review: Vol 2017 Issue 11 (Table of Contents)
Published: 4 Nov-2017
DOI: 10.3833/pdr.v2017.i11.2281 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In order to differentiate its flagship drug Opdivo® (nivolumab) amidst increasing competition, Bristol-Myers Squibb (BMS) has inked an alliance with Halozyme Therapeutics to develop subcutaneous formulations for upto 11 cancer immunotherapy targets...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS